Eli Lilly and Novo shares sold off. Don’t blame their diet pills.

stocks in

Eli Lilly


Novo Nordisk

outperformed last year, largely due to notable demand for New drug for weight loss in patients with diabetes and obesity.

Both stocks was lower this week, after companies reported December quarter results. Lilly (ticker: LLY) fell 4% through Thursday to $330.70, due to investor frustration that sales in The quarter was affected due to a decrease in the company’s demand for treatment with Covid antibodies. new (


) fell 6% to Thursday’s close of $132.34.


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button